Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31884
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLIMA, Laila
dc.contributor.authorMOLINA, Mariela da Gama Fortunato
dc.contributor.authorPEREIRA, Beatriz Sena
dc.contributor.authorNADAF, Marvin Lucas Ale
dc.contributor.authorNADAF, Maria Isabel Valdomir
dc.contributor.authorTAKANO, Olga Akiko
dc.contributor.authorCARNEIRO-SAMPAIO, Magda
dc.contributor.authorPALMEIRA, Patricia
dc.date.accessioned2019-05-30T13:42:46Z
dc.date.available2019-05-30T13:42:46Z
dc.date.issued2019
dc.identifier.citationVACCINE, v.37, n.19, p.2569-2579, 2019
dc.identifier.issn0264-410X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31884
dc.description.abstractMaternal immunization with pertussis acellular vaccine (Tdap) is an intervention that provides protection to newborns. However, it has been reported that high maternal antibody levels may adversely affect the immune response of infants after active immunization. In this study, we evaluated neonatal passive acquisition of pertussis-specific antibodies and their influence on the neonatal cell-mediated immune response. Pregnant women were either vaccinated with Tdap vaccine (case group, n = 66) or received no vaccine (control group, n = 101). Whole-cell Bordetella pertussis (Bp), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)-specific serum IgG were quantified in paired maternal-cord sera, and Bp- and PT-specific IgA were evaluated in colostrum by ELISA. Ex vivo neonatal blood lymphocyte responsiveness after Bp stimulation was assessed in case (n = 17) and control (n = 15) groups using flow cytometry to detect proliferation, cytokine production and activation phenotype of lymphocytes in the context of high specific IgG acquired after maternal vaccination. Anti-Bp, PT, FHA and PRN IgG concentrations in maternal and cord sera from case group were higher than those in control group with positive correlation indexes in both groups for all pertussis antigens. The control group presented higher placental transfer ratios of specific antibodies and, in the case group, vaccination between 26 and 31 gestation weeks was associated with the best placental transfer ratios. Specific IgA concentrations in colostrum were not affected by vaccine status. Whole blood assays revealed that newborns responded to Bp stimulation with higher expression of CD40L, CD69 and CD4(+) T cell proliferation compared to unstimulated cells, and a lower Thl response, while a preserved Th2 response compared to adults, but there were no differences between the neonatal groups for any of the studied parameters. Our results indicate that higher pertussis-specific IgG levels in newborn sera after maternal vaccination do not affect the neonatal ex vivo cell-mediated immune response.eng
dc.description.sponsorshipFAPEMAT (Fundacao de Amparo a Pesquisa do Estado de Mato Grosso, MT, Brazil) [005/2015, 221674/2015]
dc.description.sponsorshipCAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil)
dc.language.isoeng
dc.publisherELSEVIER SCI LTDeng
dc.relation.ispartofVaccine
dc.rightsrestrictedAccesseng
dc.subjectBordetella pertussiseng
dc.subjectTdap vaccine in pregnancyeng
dc.subjectIgG placental transfereng
dc.subjectNeonatal T-cell responseeng
dc.subject.otherbordetella-pertussiseng
dc.subject.otherplacental-transfereng
dc.subject.otherwhole-celleng
dc.subject.otherimmunizationeng
dc.subject.otherinfantseng
dc.subject.otherprotectioneng
dc.subject.othercytokineseng
dc.titleAcquisition of specific antibodies and their influence on cell-mediated immune response in neonatal cord blood after maternal pertussis vaccination during pregnancyeng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIER SCI LTDeng
dc.identifier.doi10.1016/j.vaccine.2019.03.070
dc.identifier.pmid30955978
dc.subject.wosImmunologyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalMOLINA, Mariela da Gama Fortunato:Univ Fed Mato Grosso, Dept Pediat, Cuiaba, MT, Brazil
hcfmusp.author.externalNADAF, Marvin Lucas Ale:Univ Fed Mato Grosso, Dept Pediat, Cuiaba, MT, Brazil
hcfmusp.author.externalNADAF, Maria Isabel Valdomir:Univ Fed Mato Grosso, Dept Pediat, Cuiaba, MT, Brazil
hcfmusp.author.externalTAKANO, Olga Akiko:Univ Fed Mato Grosso, Dept Pediat, Cuiaba, MT, Brazil
hcfmusp.description.beginpage2569
hcfmusp.description.endpage2579
hcfmusp.description.issue19
hcfmusp.description.volume37
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000466248800007
hcfmusp.origem.id2-s2.0-85063758914
hcfmusp.publisher.cityOXFORDeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAbu Raya B, 2014, VACCINE, V32, P5632, DOI 10.1016/j.vaccine.2014.08.006eng
hcfmusp.relation.referenceAgarwal S, 2011, J HUM LACT, V27, P171, DOI 10.1177/0890334410395761eng
hcfmusp.relation.referenceBasha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288eng
hcfmusp.relation.referenceBoulton Jacqueline, 2013, Br J Nurs, V22, P1046eng
hcfmusp.relation.referenceCarbonetti NH, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv073eng
hcfmusp.relation.referenceCarollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104eng
hcfmusp.relation.referenceDenkinger CM, 2007, CELL IMMUNOL, V246, P46, DOI 10.1016/j.cellimm.2007.05.004eng
hcfmusp.relation.referenceDirix V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/795958eng
hcfmusp.relation.referenceDubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.xeng
hcfmusp.relation.referenceEnglund JA, 2007, J COMP PATHOL, V137, pS16, DOI 10.1016/j.jcpa.2007.04.006eng
hcfmusp.relation.referenceGoenka A, 2015, J INFECTION, V71, pS112, DOI 10.1016/j.jinf.2015.04.027eng
hcfmusp.relation.referenceGrondahl-Yli-Hannuksela K, 2016, VACCINE, V34, P341, DOI 10.1016/j.vaccine.2015.11.049eng
hcfmusp.relation.referenceHoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098eng
hcfmusp.relation.referenceHealy CM, 2007, PEDIATR INFECT DIS J, V26, P945, DOI 10.1097/INF.0b013e318156c18ceng
hcfmusp.relation.referenceHodder SL, 2000, CLIN INFECT DIS, V31, P7, DOI 10.1086/313913eng
hcfmusp.relation.referenceJones C, 2014, VACCINE, V32, P996, DOI 10.1016/j.vaccine.2013.11.104eng
hcfmusp.relation.referenceLe Doare K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01269eng
hcfmusp.relation.referenceMaertens K, 2014, VACCINE, V32, P1786, DOI 10.1016/j.vaccine.2014.01.083eng
hcfmusp.relation.referenceMattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005eng
hcfmusp.relation.referenceMcGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288eng
hcfmusp.relation.referenceMills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6eng
hcfmusp.relation.referenceMinisterio da Saude (BR). Secretaria de Vigilancia em Saude, 2015, B EPIDEMIOL, V46, P1eng
hcfmusp.relation.referenceMiyano Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064777eng
hcfmusp.relation.referenceMunoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633eng
hcfmusp.relation.referenceNagao AT, 1998, SCAND J IMMUNOL, V47, P609eng
hcfmusp.relation.referenceNaidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002eng
hcfmusp.relation.referenceNieves DJ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0008-2015eng
hcfmusp.relation.referenceNiewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446eng
hcfmusp.relation.referencePalazzo R, 2016, NEW MICROBIOL, V39, P35eng
hcfmusp.relation.referencePalmeira P, 2016, REV ASSOC MED BRAS, V62, P584, DOI 10.1590/1806-9282.62.06.584eng
hcfmusp.relation.referencePalmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646eng
hcfmusp.relation.referencePandolfi E, 2017, PEDIATR INFECT DIS J, V36, pE48, DOI 10.1097/INF.0000000000001418eng
hcfmusp.relation.referencePlotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10eng
hcfmusp.relation.referenceQuinello C, 2010, SCAND J IMMUNOL, V72, P66, DOI 10.1111/j.1365-3083.2010.02410.xeng
hcfmusp.relation.referenceRaphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011eng
hcfmusp.relation.referenceRaya B. A., 2014, Vaccine, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038eng
hcfmusp.relation.referenceSaso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9eng
hcfmusp.relation.referenceShahid NS, 2002, VACCINE, V20, P2404, DOI 10.1016/S0264-410X(02)00061-0eng
hcfmusp.relation.referenceSiegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6eng
hcfmusp.relation.referenceSimister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7eng
hcfmusp.relation.referenceSmits K, 2013, VACCINE, V32, P111, DOI 10.1016/j.vaccine.2013.10.056eng
hcfmusp.relation.referenceSoares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007eng
hcfmusp.relation.referenceVermeulen F, 2010, CLIN VACCINE IMMUNOL, V17, P258, DOI 10.1128/CVI.00328-09eng
hcfmusp.relation.referenceWHICHER JT, 1983, CRC CR REV CL LAB SC, V18, P213eng
hcfmusp.relation.referenceWinter K, 2012, J PEDIATR-US, V161, P1091, DOI 10.1016/j.jpeds.2012.05.041eng
hcfmusp.relation.referenceWolfe DN, 2007, J INFECT DIS, V196, P1228, DOI 10.1086/521303eng
hcfmusp.relation.referenceWorld Health Organization, 2016, VACC PREV DIS MON SYeng
hcfmusp.relation.reference2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/CID/CIU821eng
hcfmusp.relation.reference2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0B013E3182A09B6Aeng
dc.description.indexMEDLINEeng
dc.identifier.eissn1873-2518
hcfmusp.citation.scopus12-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - LIM/43
LIM/43 - Laboratório de Medicina Nuclear

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_LIMA_Acquisition_of_specific_antibodies_and_their_influence_on_2019.PDF
  Restricted Access
publishedVersion (English)618.37 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.